PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-4.59%
Cash & equivalents declining -4.59% while AVXL's grows 27.17%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
-40.54%
Both AVXL and the company show zero Short-Term Investments Growth.
-4.61%
Below half of AVXL's 27.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of AVXL's 26.38%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
10.64%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.58%
Higher Total Non-Current Assets Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half of AVXL's 26.37%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-12.14%
Similar yoy growth to AVXL's -13.60%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
-100.00%
Less than half of AVXL's 2.33%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of AVXL's 13.60%. Michael Burry suspects a big gap in pre-sales traction.
-34.95%
Less than half of AVXL's 72042194092826896.00%. David Dodd sees fewer expansions in other current obligations.
-29.36%
Similar yoy to AVXL's -34.47%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.36%
Similar yoy to AVXL's -38.72%. Walter Schloss sees parallel expansions in total liabilities.
3.53%
Less than half of AVXL's 47.30%. David Dodd sees fewer share issuances vs. competitor.
-3.88%
Below half AVXL's -10.11%. Michael Burry suspects major net losses or high dividends vs. competitor.
-25.46%
1.25-1.5x AVXL's -19.59%. Martin Whitman is wary of bigger swings in AOCI.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
Below half AVXL's 49.38%. Michael Burry sees potential underperformance in building shareholder capital.
-4.86%
Below half AVXL's 26.37%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-40.54%
Both AVXL and the company show zero Total Investments Growth.
-100.00%
Above 1.5x AVXL's -52.08%. Michael Burry sees a major jump. Investigate leverage rationale.
4.24%
Less than half of AVXL's -30.09%. David Dodd sees better deleveraging or stronger cash buildup than competitor.